Fortress Biotech, Inc. (FBIO)
| Market Cap | 55.82M |
| Revenue (ttm) | 57.78M |
| Net Income (ttm) | -50.75M |
| Shares Out | 29.53M |
| EPS (ttm) | -2.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 110,286 |
| Open | 1.920 |
| Previous Close | 1.950 |
| Day's Range | 1.840 - 1.940 |
| 52-Week Range | 1.325 - 2.890 |
| Beta | 1.86 |
| Analysts | Strong Buy |
| Price Target | 21.00 (+1,011.11%) |
| Earnings Date | May 15, 2025 |
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for... [Read more]
Financial Performance
In 2024, Fortress Biotech's revenue was $57.68 million, a decrease of -31.76% compared to the previous year's $84.51 million. Losses were -$55.89 million, -18.61% less than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 1,011.11% from the latest price.
News
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cos...
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoi...
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions ...
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses ...
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary...
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and o...
Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript
Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, ...
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended D...
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Med...
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic ...
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and ma...
Sun Pharma to Acquire Checkpoint Therapeutics
Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm...
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”)...
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety is...
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults...
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T. Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E...
Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease
Six-month priority review granted for CUTX-101 copper histidinate with PDUFA target action date set for June 30, 2025 CUTX-101 has potential to be the first FDA-approved treatment for Menkes disease, ...
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones C...
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous ...
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally adv...